Merck (NYSE:MRK) is doubling down on China's biotech boomthis time with a $2 billion licensing deal for a potential blockbuster heart drug from Jiangsu Hengrui Pharmaceuticals. The deal gives ...

Most recently, Danish drugmaker Novo Nordisk bought global rights to China-based United Laboratories International's weight-loss drug candidate in a deal worth up to $2 billion. Merck last year ...

noting that the company has a full value chain including its own factory in China with a lot of local manufacturing. Merck also has a healthcare innovation center in China and has now established ...